Key result
TRPV2 is necessary for normal cardiac contractility, TRPV1 activation protects against ischemia/reperfusion injury via CGRP release, and TRPV4 activation exacerbates ischemic injury.
TRPV channels play distinct physiological and pathological roles in the heart, with TRPV4 blockade and TRPV1 activation emerging as potential therapeutic strategies for ischemia/reperfusion injury.
TRPV2-targeted therapies merit preclinical testing in contractility disorders; leaves open clinical translation pending RCTs.
Transient receptor potential vanilloid channel 2 (TRPV2) is required for normal cardiac contractility. The stimulation of TRPV1 in isolated cardiomyocytes can aggravate the effect of hypoxia/ reoxygenation (H/R) on H9C2 cells. The knockout of the TRPV1 gene promotes increased tolerance of the isolated perfused heart to the impact of ischemia/reperfusion (I/R). However, activation of TRPV1 increases the resistance of the heart to I/R due to calcitonin gene-related peptide (CGRP) release from afferent nerve endings. It has been established that TRPV1 and TRPV2 are involved in the pathogenesis of myocardial infarction and, in all likelihood, ensure the cardiac tolerance to the ischemia/reperfusion. It has also been documented that the activation of TRPV4 negatively affects the stability of cardiomyocytes to the H/R. The blockade of TRPV4 can be considered as a new approach to the prevention of I/R injury of the heart. Studies also indicate that TRPV1 is involved in the pathogenesis of cardiac hypertrophy and that TRPV2 channels participate in the pathogenesis of dilated cardiomyopathy. Excessive expression of TRPV2 leads to chronic Ca2+- overload of cardiomyocytes, which may contribute to the development of cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Gorbunov et al. (2019) conducted a review in Cardiovascular disease. TRPV1, TRPV2, and TRPV4 modulators was evaluated. TRPV2 is necessary for normal cardiac contractility, TRPV1 activation protects against ischemia/reperfusion injury via CGRP release, and TRPV4 activation exacerbates ischemic injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: